NCT01969682View on ClinicalTrials.gov

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

ABT-199

Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin

DRUG

Rifampin

Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin

Trial Locations (1)

07601

Site Reference ID/Investigator# 101416, Hackensack

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie

INDUSTRY